Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 4053 record(s)

Req # A-2024-000017

Adverse Drug Reaction (ADR) for ACITRETIN. Report number: 1071472. ADRs for ANASTROZOLE. Report numbers: 983160, 990116. ADR for CIPROFLOX. Report number: 1032025. ADR for Clonidine. Report number: 981372. ADRs for EPLERENONE. Reports number:…

Organization: Health Canada

70 page(s)
April 2024

Req # A-2024-000028

Adverse Drug Reactions (ADRs) for Rosuvastatin-40. Report numbers: 000657015, 000702528. ADRs for Rosuvastatin-10. Report numbers: 000675846, 000928844. ADRs for Rosuvastatin-5. Report numbers: 000698101, 000705573. ADRs for Rosuvastatin-20. Report…

Organization: Health Canada

29 page(s)
April 2024

Req # A-2024-000032

Adverse Drug Reactions (ADRs) for IBUPROFEN. Report numbers: 001049833, 001051635, 001052031, 001052040, 001052619, 001050859, 001053224, 001055320, 001065019, 001065607.

Organization: Health Canada

76 page(s)
April 2024

Req # A-2024-000068

Adverse Drug Reaction (ADR) for YESCARTA. Report number: 001076510.

Organization: Health Canada

3 page(s)
April 2024

Req # A-2016-000420

Documents relating to Health Canada’s approval of INFLECTRA (Drug Identification Number (DIN) # 02419475): All Health Canada reviewers reports and reviewer comments; and all minutes from any pre-Supplement to a New Drug Submission (SNDS) meetings…

Organization: Health Canada

299 page(s)
March 2024

Req # A-2019-001464

All domestic Adverse Drug Reaction (ADR) reports for Tetanus, Diphtheria and Pertussis (Tdap) Hepatitis B, Measles, Mumps and Rubella (MMR), Varicelli, Inactivated Polio Vaccine (IPV), Diphtheria, Tetanus and Pertussis (DTaP), Flu for the period of…

Organization: Health Canada

3917 page(s)
March 2024

Req # A-2019-001525

The Clinical Overview, Clinical Summary of Efficacy and Clinical Summary of Safety submitted to Health Canada as part of the Supplemental New Drug Submission (SNDS) (control number: 204690; decision date: 2018-03-29) in respect of TALTZ.

Organization: Health Canada

898 page(s)
March 2024

Req # A-2020-001374

For the period 2015 to April 19, 2021, and in relation to natural health product brand names containing the phrase “glucosamine sulfate” or “glucosamine sulphate”, with license holders named WN Pharmaceuticals Ltd, Natural Factors Nutritional…

Organization: Health Canada

1565 page(s)
March 2024

Req # A-2021-001830

A summary of the costs incurred to develop, advertise, and run the COVID Alert App program mentioned in this news story: https://globalnews.ca/news/8478550/attempts-improve-covid-alert-stall-lack-of-interest-provinces/. Records from the start of the…

Organization: Health Canada

15 page(s)
March 2024

Req # A-2021-001944

An analysis of the hazards present at the site and quantify any potential risk of historical exposusres, Canada Training Centre in Kemptville Ontario by Bluemetric Environmental Inc. A copy of this report as well as all all communications between…

Organization: Health Canada

111 page(s)
March 2024
Date modified: